IINN VS CNTX Stock Comparison

Performance

IINN
10/100

IINN returned -8.60% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CNTX
66/100

CNTX returned -17.89% in the last 12 months. Based on SPY's performance of -21.29%, its performance is above average giving it a score of 65 of 100.

Sentiment

IINN
64/100

IINN had a bullish sentiment score of 63.94% across Twitter and StockTwits over the last 12 months. It had an average of 2.16 posts, 0.42 comments, and 2.10 likes per day.

CNTX
70/100

CNTX had a bullish sentiment score of 69.84% across Twitter and StockTwits over the last 12 months. It had an average of 27.35 posts, 16.22 comments, and 86.78 likes per day.

Technicals

IINN
10/100

IINN receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

CNTX
21/100

CNTX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

IINN
100/100

IINN has missed earnings 0 times in the last 20 quarters.

CNTX
20/100

CNTX has missed earnings 3 times in the last 20 quarters.

Profit

IINN
21/100

Out of the last 18 quarters, IINN has had 3 profitable quarters and has increased their profits year over year on 3 of them.

CNTX
10/100

Out of the last 14 quarters, CNTX has had 2 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

IINN
40/100

IINN has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

CNTX
58/100

CNTX has had a higher than average amount of volatility over the last 12 months giving it a score of 58 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares Summary

Nasdaq / IINN

Healthcare

Medical - Devices

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.

Context Therapeutics Inc. Common Stock Summary

Nasdaq / CNTX

Healthcare

Biotechnology

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Power up your portfolio